ChiCTR1900021449 版本V1.0 版本创建时间2019/02/24 18:25:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900021449 

最近更新日期:

Date of Last Refreshed on:

2019-02-21 22:23:26 

注册时间:

Date of Registration:

2019-02-21 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

前列腺內視鏡手術療效研究

Public title:

Transurethral surgery of prostate: efficacy comparison

注册题目简写:

English Acronym:

研究课题的正式科学名称:

多種雷射汽化切除術與雙極電刀前列腺刮除術治療前列腺肥大症之結果比較

Scientific title:

Comparison of Various Laser Vaporesection versus Plasmakinetic Resection for Treatment of Benign Prostate Obstruction

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

許富順 

研究负责人:

許富順 

Applicant:

Fu-Shun, Hsu 

Study leader:

Fu-Shun, Hsu 

申请注册联系人电话:

Applicant telephone:

+886 921566304

研究负责人电话:

Study leader's
telephone:

+886 921566304

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

fs_hsu@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

fs_hsu@outlook.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中國臺灣臺北市中山區長安東路二段111號6樓

研究负责人通讯地址:

中國臺灣臺北市中山區長安東路二段111號6樓

Applicant address:

6F, 111 Second Section, Chan-An Road East, Taipei, Taiwan, China

Study leader's address:

6F, 111 Second Section, Chan-An Road East, Taipei, Taiwan, China

申请注册联系人邮政编码:

Applicant postcode:

10455

研究负责人邮政编码:

Study leader's postcode:

10455

申请人所在单位:

新北市立聯合醫院

Applicant's institution:

New Taipei City Hospital

研究负责人所在单位:

新北市立聯合醫院

Affiliation of the Leader:

New Taipei City Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

105005-E

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

人體研究倫理審查委員會

Name of the ethic committee:

Research Ethics Review Committee, New Taipei City Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

張皓程

Contact Name of the ethic committee:

How-Chen, Chang

伦理委员会联系地址:

中國臺灣新北市板橋區英士路198號

Contact Address of the ethic committee:

198 In-Xi Road, Banciao District, New Taipei City, Taiwan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

泌尿科

Primary sponsor:

Department of Urology

研究实施负责(组长)单位地址:

中國臺灣新北市板橋區英士路198號

Primary sponsor's address:

198 In-Xi Road, Banciao District, New Taipei City, Taiwan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中國

省(直辖市):

臺灣

市(区县):

新北市

Country:

China

Province:

Taiwan

City:

New Taipei City

单位(医院):

泌尿科

具体地址:

新北市板橋區英士路198號

Institution
hospital:

Department of Urology

Address:

198 In-Xi Road, Banciao District, New Taipei City

经费或物资来源:

臺灣楓城泌尿學會

Source(s) of funding:

Taiwan Maple Urological Association

研究疾病:

前列腺  

Target disease:

Prostate

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

可了解不同前列腺內視鏡手術方式(工具)之臨床療效與併發症之差別,以確立對病患最有效或併發症最少的治療方式。  

Objectives of Study:

This study is a prospective, single-center, clinical observation to compare the effectiveness and safety between various transurethral prostate surgeries in New Taipei City Hospital, Taiwan. We plan to enroll all eligible patients with benign prostate enlargement and lower urinary tract symptoms who received transurethral surgery of prostate, including transurethral resection of prostate with monopolar electocautery (TURP), plasmakinetic resection of the prostate (PKRP), multipulse laser vaporesection of the prostate (MPVP), greenlight laser vaporesection of the prostate (GRP), thulium laser resection of the prostate (ThuRP) and diode laser vaporesection of the prostate (DRP).

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 男性病人超過50歲
2.國際前列腺症狀評分表(IPSS)>=10分
3.平均尿流速<15cc/sec
4.在篩選時間內接受攝護腺內視鏡手術患者

Inclusion criteria

patient aged older than 50 years, maximum flow rate (Qmax) < 15 mL/second and the International Prostate Symptom Score (IPSS) ≥ 10. All subjects received quality-of-life questionnaire (QoL) and transrectal ultrasound of the prostate (TRUS) preoperatively.

排除标准:

1. 已表明不願接受此研究的患者。
2. 前列腺癌或膀胱癌患者。
3. 之前接受過經尿道手術者。
4. 合併有其他原因的神經性膀胱患者

Exclusion criteria:

Patients with prostate cancer, bladder cancer, previous transurethral surgery, interstitial cystitis and neurogenic bladder were excluded.

研究实施时间:

Study execute time:

From 2016-01-01 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-01-01 00:00:00 To 2020-09-30 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

80

Group:

1

Sample size:

干预措施:

單極電刀刮除術

干预措施代码:

Intervention:

transurethral resection of prostate with monopolar electocautery (TURP)

Intervention code:

组别:

2

样本量:

80

Group:

2

Sample size:

干预措施:

雙極電刀刮除術

干预措施代码:

Intervention:

plasmakinetic resection of the prostate (PKRP)

Intervention code:

组别:

3

样本量:

80

Group:

3

Sample size:

干预措施:

多波光雷射氣化切除術

干预措施代码:

Intervention:

multipulse laser vaporesection of the prostate (MPVP)

Intervention code:

组别:

4

样本量:

80

Group:

4

Sample size:

干预措施:

綠光雷射汽化術

干预措施代码:

Intervention:

greenlight laser vaporesection of the prostate (GRP)

Intervention code:

组别:

5

样本量:

100

Group:

5

Sample size:

干预措施:

銩雷射氣化切除術

干预措施代码:

Intervention:

thulium laser resection of the prostate (ThuRP)

Intervention code:

组别:

6

样本量:

80

Group:

6

Sample size:

干预措施:

紅激光雷射汽化術

干预措施代码:

Intervention:

diode laser vaporesection of the prostate (DRP)

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中國

省(直辖市):

臺灣 

市(区县):

新北市 

Country:

China

Province:

Taiwan

City:

New Taipei City

单位(医院):

新北市立聯合醫院 

单位级别:

 

Institution
hospital:

New Taipei City Hospital

Level of the institution:

测量指标:

Outcomes:

指标中文名:

國際前列腺症狀分數

指标类型:

主要指标

Outcome:

IPSS

Type:

Primary indicator

测量时间点:

術前,術後1, 3, 6, 12個月

测量方法:

症狀表

Measure time point of outcome:

preoperative, postoperative 1, 3, 6, 12 months

Measure method:

symptom score

指标中文名:

最大尿流速

指标类型:

次要指标

Outcome:

Maximal uroflowrate

Type:

Secondary indicator

测量时间点:

術前,術後1, 3, 6, 12個月

测量方法:

機器

Measure time point of outcome:

preoperative, postoperative 1, 3, 6, 12 months

Measure method:

Uroflowrate machine

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 50 years
最大 Max age 98 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

無隨機

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-randomized study

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

不公開

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Private

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2019-02-21 22:23:26